Factors Associated with Anti-SARS-CoV-2 Vaccine Acceptance among Pregnant Women: Data from Outpatient Women Experiencing High-Risk Pregnancy
- PMID: 36851330
- PMCID: PMC9966581
- DOI: 10.3390/vaccines11020454
Factors Associated with Anti-SARS-CoV-2 Vaccine Acceptance among Pregnant Women: Data from Outpatient Women Experiencing High-Risk Pregnancy
Abstract
Pregnant women are at higher risk of severe Coronavirus disease 2019 (COVID-19) complications than non-pregnant women. The initial exclusion of pregnant women from anti-SARS-CoV-2 vaccines clinical trials has caused a lack of conclusive data about safety and efficacy for this vulnerable population. This cross-sectional study aims to define the factors related to vaccination adherence in a sample of women experiencing high-risk pregnancies. The recruited women completed a questionnaire based on the Health Belief Model. Data were analyzed to evaluate the associations between socio-demographic variables and vaccination acceptance through descriptive, univariate and multivariate logistic analyses. Among the 233 women enrolled, 65.2% (n = 152) declared that they would accept the anti-SARS-CoV-2 vaccine. Multivariate analysis showed that vaccination acceptance was associated with a high educational level (aOR = 4.52, p = 0.001), a low perception of barriers to vaccination (aOR = 1.58, p = 0.005) and the gynecologist's advice (aOR = 3.18, p = 0.01). About a third of pregnant women are still hesitant about the anti-SARS-CoV-2 vaccine, probably because of the conflicting information received from media, friends, acquaintances and health institutions. Determining factors linked to vaccine hesitancy among pregnant women is useful for creating vaccination strategies that increase vaccination uptake.
Keywords: COVID; Health Belief Model; anti-SARS-CoV-2 vaccination; barrier; communication; educational level; gynecologist; high-risk pregnant women; vaccine acceptance; vaccine hesitancy.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- European Centre for Disease Prevention and Control COVID-19 Updates. [(accessed on 13 September 2022)]; Available online: https://www.ecdc.europa.eu/en/covid-19.
-
- Fedele G., Trentini F., Schiavoni I., Abrignani S., Antonelli G., Baldo V., Baldovin T., Bandera A., Bonura F., Clerici P., et al. Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study. Front. Immunol. 2022;13:1021396. doi: 10.3389/fimmu.2022.1021396. - DOI - PMC - PubMed
-
- Allotey P., Stallings E., Bonet M., Yap M., Chatterjee S., Kew T., Debenham L., Llavall A.C., Dixit A., Zhou D., et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: Living systematic review and meta-analysis. BMJ. 2020;370:m3320. doi: 10.1136/bmj.m3320. - DOI - PMC - PubMed
-
- Gullo G., Cucinella G., Tumminello M., Renda B., Donzelli M., Lo Bue V., Termini D., Maranto M., De Tommasi O., Tarantino F. Convalescent plasma use in pregnant patients with COVID-19 related ARDS: A case report and a literature review. Ital. J. Gynaecol. Obstet. 2022;34:228–234. doi: 10.36129/jog.2022.32. - DOI
LinkOut - more resources
Full Text Sources
Miscellaneous
